Form 4: STAAR Surgical Co-CEO Granted 39,809 RSUs

STAAR Surgical's Interim Co-CEO and CFO, Deborah J. Andrews, was granted 39,809 restricted stock units vesting over three years.

Summary

• Deborah J. Andrews, Interim Co-CEO and CFO of STAAR SURGICAL CO, received a grant of 39,809 Restricted Stock Units (RSUs).
• Each RSU represents the right to receive one share of the company's common stock upon vesting.
• The RSUs were granted on March 13, 2026, as part of an annual equity award.
• The vesting schedule is 1/3 (13,269 shares) on March 13, 2027, 1/3 (13,270 shares) on March 13, 2028, and 1/3 (13,270 shares) on March 13, 2029.
• Following this transaction, Deborah J. Andrews beneficially owns 39,809 derivative securities (RSUs).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting standard executive compensation practices designed to align management incentives with shareholder interests over the long term.

Positives

• The grant of restricted stock units aligns the interests of the Interim Co-CEO and CFO with long-term shareholder value.
• Equity awards are a common incentive for executive retention and performance.

Future Outlook

The vesting schedule for the restricted stock units extends through March 2029, indicating a long-term incentive structure for the Interim Co-CEO and CFO.

Industry Context

StockSavvy.ai notes that equity compensation, such as restricted stock units, is a standard practice across various industries, including medical devices, to incentivize and retain key executives. This grant is consistent with typical executive compensation structures in publicly traded companies.

Comparison to Industry Standards

• The grant of RSUs to a senior executive like an Interim Co-CEO and CFO is a common compensation practice, comparable to similar awards seen at companies such as Alcon (ALC) or Bausch + Lomb (BLCO) in the ophthalmic or medical device sector, aiming to align executive interests with long-term company performance.
• The three-year vesting schedule is a standard industry practice for equity awards, providing a long-term retention mechanism for key personnel.

Stakeholder Impact

• Shareholders: Potential for increased alignment of executive interests with long-term company performance.
• Employees: Standard executive compensation practices can influence overall company morale and compensation structures.

Next Steps

• Vesting of 13,269 RSUs on March 13, 2027.
• Vesting of 13,270 RSUs on March 13, 2028.
• Vesting of 13,270 RSUs on March 13, 2029.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a senior executive, which is a standard component of executive compensation. It does not provide new information that would fundamentally alter the investment thesis for STAAR Surgical Co, thus a 'hold' recommendation is appropriate based solely on this filing.

Keywords

STAAR Surgical, STAA, Restricted Stock Units, RSU, Insider Trading, Equity Award, Executive Compensation, Deborah J. Andrews, Form 4